Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 20/20 | 1.00 |
| ▸ | SLC6A5 | Q9Y345 | 3/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5222857 | 1.00 | SLC6A9 (1.00) | SLC6A9SLC6A5KCNH2 | |
| SCHEMBL1461318 | 1.00 | SLC6A9 (1.00) | SLC6A9SLC6A5KCNH2 | |
| SCHEMBL18490920 | 0.94 | SLC6A9 (0.89) | SLC6A9SLC6A5KCNH2 | |
| SCHEMBL3872054 | 0.93 | SLC6A9 (1.00) | SLC6A9SLC6A5KCNH2 | |
| SCHEMBL3878358 | 0.91 | SLC6A9 (0.84) | SLC6A9SLC6A5KCNH2 | |
| SCHEMBL18502987 | 0.90 | SLC6A9 (0.82) | SLC6A9SLC6A5 | |
| SCHEMBL9882712 | 0.90 | SLC6A9 (0.84) | SLC6A9SLC6A5KCNH2 | |
| SCHEMBL9882711 | 0.90 | SLC6A9 (0.84) | SLC6A9SLC6A5KCNH2 | |
| SCHEMBL3871584 | 0.90 | SLC6A9 (0.81) | SLC6A9SLC6A5 | |
| SCHEMBL3880029 | 0.89 | SLC6A9 (0.80) | SLC6A9SLC6A5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106163520-B | GLYT1 inhibitors for the treatment of hematological disorders | 豪夫迈·罗氏有限公司 | 2019-12-13 | — | — | CN | claimed |
| EP-3137073-B1 | GLYT1 INHIBITORS FOR USE IN THE TREATMENT OF HEMATOLOGICAL DISORDERS | HOFFMANN LA ROCHE (CH) | 2018-06-06 | — | — | EP | claimed |
| US-9877963-B2 | GlyT1 inhibitors for use in the treatment of hematological disorders | HOFFMANN-LA ROCHE INC. (US) | 2018-01-30 | — | — | US | claimed |
| EP-3137073-A1 | GLYT1 INHIBITORS FOR USE IN THE TREATMENT OF HEMATOLOGICAL DISORDERS | F. Hoffmann-La Roche AG (CH) | 2017-03-08 | — | — | EP | claimed |
| US-20170042888-A1 | GLYT1 INHIBITORS FOR USE IN THE TREATMENT OF HEMATOLOGICAL DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 2017-02-16 | — | — | US | claimed |
| WO-2015165842-A1 | GLYT1 INHIBITORS FOR USE IN THE TREATMENT OF HEMATOLOGICAL DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-11-05 | — | — | WO | claimed |
| EP-1848694-B1 | HETEROCYCLIC SUBSTITUTED PHENYL METHANONES AS INHIBITORS OF THE GLYCINE TRANSPORTER 1 | HOFFMANN LA ROCHE (CH) | 2009-11-25 | — | — | EP | claimed |
| US-7557114-B2 | Heterocyclic-substituted phenyl methanones | HOFFMAN-LA ROCHE INC. (US) | 2009-07-07 | — | — | US | claimed |
| US-20060178381-A1 | Heterocyclic-substituted phenyl methanones | HOFFMANN-LA ROCHE INC. | 2006-08-10 | — | — | US | claimed |
| CN-106163520-B | GLYT1 inhibitors for the treatment of hematological disorders | 豪夫迈·罗氏有限公司 | 2019-12-13 | — | — | CN | disclosed |
| EP-3137073-B1 | GLYT1 INHIBITORS FOR USE IN THE TREATMENT OF HEMATOLOGICAL DISORDERS | HOFFMANN LA ROCHE (CH) | 2018-06-06 | — | — | EP | disclosed |
| EP-3137073-B1 | GLYT1 INHIBITORS FOR USE IN THE TREATMENT OF HEMATOLOGICAL DISORDERS | HOFFMANN LA ROCHE (CH) | 2018-06-06 | — | — | EP | disclosed |
| US-9877963-B2 | GlyT1 inhibitors for use in the treatment of hematological disorders | HOFFMANN-LA ROCHE INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-9877963-B2 | GlyT1 inhibitors for use in the treatment of hematological disorders | HOFFMANN-LA ROCHE INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-7557114-B2 | Heterocyclic-substituted phenyl methanones | HOFFMAN-LA ROCHE INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557114-B2 | Heterocyclic-substituted phenyl methanones | HOFFMAN-LA ROCHE INC. (US) | 2009-07-07 | — | — | US | disclosed |
| WO-2009068463-A2 | PROCESS FOR THE PREPARATION OF ISOINDOLE DERIVATIVES AS WELL AS A PROCESS FOR THE PREPARATION OF THEIR INTERMEDIATES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-04 | — | — | WO | disclosed |
| EP-1848694-A1 | HETEROCYCLIC SUBSTITUTED PHENYL METHANONES AS INHIBITORS OF THE GLYCINE TRANSPORTER 1 | F. Hoffmann-Roche AG (CH) | 2007-10-31 | — | — | EP | disclosed |
| WO-2006082001-A1 | HETEROCYCLIC SUBSTITUTED PHENYL METHANONES AS INHIBITORS OF THE GLYCINE TRANSPORTER 1 | F.HOFFMANN-LA ROCHE AG (CH) | 2006-08-10 | — | — | WO | disclosed |
| US-20060178381-A1 | Heterocyclic-substituted phenyl methanones | HOFFMANN-LA ROCHE INC. | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178381-A1 | Heterocyclic-substituted phenyl methanones | CYP2B6, CYP2D6, CYP1A2 | SLC6A9 1024/4885SLC6A5 639/4885KCNH2 1197/4885 |
| US-20170042888-A1 | GLYT1 INHIBITORS FOR USE IN THE TREATMENT OF HEMATOLOGICAL DISORDERS | SLC40A1, GFPT1, HBG1 | SLC6A9 121/4885SLC6A5 142/4885KCNH2 3010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.